Spero Therapeutics Files 8-K on Jan 8, Signals New Material Info

Ticker: SPRO · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1701108

Spero Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpero Therapeutics, Inc. (SPRO)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, corporate-update

TL;DR

**Spero Therapeutics just dropped an 8-K, new info coming that could move SPRO.**

AI Summary

Spero Therapeutics, Inc. filed an 8-K on January 8, 2024, to report a current event. This filing, under Regulation FD Disclosure and Financial Statements and Exhibits, indicates that the company is providing information that may be material to investors. For shareholders, this means Spero is making new information public, which could influence the stock price (SPRO) as investors digest the details of the undisclosed event.

Why It Matters

This 8-K signals that Spero Therapeutics has new, potentially important information to share, which could impact investor perception and the company's stock performance.

Risk Assessment

Risk Level: medium — The filing itself doesn't detail the event, creating uncertainty about its nature and potential impact on Spero Therapeutics.

Analyst Insight

A smart investor would monitor Spero Therapeutics (SPRO) closely for subsequent announcements or filings that detail the specific event referenced in this 8-K, as the nature of the disclosure could significantly impact the stock.

Key Numbers

  • 001-38266 — Commission File Number (identifies Spero Therapeutics' registration with the SEC)
  • 46-4590683 — I.R.S. Employer Identification No. (identifies Spero Therapeutics for tax purposes)
  • 857-242-1600 — Registrant's telephone number (contact information for Spero Therapeutics)

Key Players & Entities

  • Spero Therapeutics, Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • SPRO (company) — trading symbol for Spero Therapeutics, Inc.
  • The Nasdaq Global Select Market (company) — exchange where SPRO is registered
  • 001-38266 (dollar_amount) — Commission File Number

Forward-Looking Statements

  • Spero Therapeutics will release more specific details about the event mentioned in this 8-K within the next few days. (Spero Therapeutics, Inc.) — high confidence, target: 2024-01-15
  • The undisclosed event will likely relate to either clinical trial results, a new partnership, or a financing activity. (Spero Therapeutics, Inc.) — medium confidence, target: 2024-03-31

FAQ

What is the primary purpose of this 8-K filing by Spero Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report a current event that occurred on January 8, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits, indicating the disclosure of potentially material information.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024.

What is the trading symbol and the exchange where Spero Therapeutics, Inc. common stock is registered?

Spero Therapeutics, Inc.'s common stock trades under the symbol SPRO and is registered on The Nasdaq Global Select Market.

What is the business address of Spero Therapeutics, Inc. as stated in the filing?

The business address of Spero Therapeutics, Inc. is 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02140.

Does this 8-K filing provide specific details about the nature of the event being disclosed?

No, this 8-K filing does not provide specific details about the nature of the event being disclosed, only that it falls under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.

Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-01-08 06:07:02

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On January 8, 2024, Spero Therapeutics, Inc. (the "Company") updated its investor presentation (the "Investor Presentation"), which the Company expects to use in connection with general corporate presentations and will be made available on the Company's website or distributed by the Company in hardcopy or electronic form. A copy of the Investor Presentation is attached as Exhibit 99.1 to this Current Report. The Investor Presentation is current as of January 8, 2024, and the Company disclaims any obligation to update the Investor Presentation after such date. In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the Investor Presentation is "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation of Spero Therapeutics, Inc. dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 SPERO THERAPEUTICS, INC. By: /s/ Tamara Joseph Tamara Joseph Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.